TY - JOUR T1 - Teriparatide for Glucocorticoid-induced Osteoporosis JF - The Journal of Rheumatology JO - J Rheumatol SP - 461 LP - 462 DO - 10.3899/jrheum.111629 VL - 39 IS - 3 AU - ADOLFO DIEZ-PEREZ AU - EMILIA SOLE Y1 - 2012/03/01 UR - http://www.jrheum.org/content/39/3/461.abstract N2 - Efficacy trials have been widely considered to rank at the highest level of published evidence. Although this is certainly a major advance in the field of clinical research, results of clinical trials have some important limitations when applied to everyday patients. Besides the fact that the studied population does not necessarily behave in a similar fashion across different countries, races, practices, or health-care systems1, the population included in such trials has usually been carefully selected to assess individuals as “cleanly” as possible with respect to the disease and outcomes as defined in the study design. However, in clinical practice, in the vast majority of cases patients suffer from other diseases, receive other drugs, and adhere to treatments very differently. It has been estimated that up to 80% of patients asking for osteoporosis care would be excluded from osteoporosis trials2. Hence the importance of well designed observational studies where patients, interventions, and results are identical to what we deal with in our everyday practice. Only pragmatic or naturalistic studies can overcome the gap between efficacy and effectiveness.Teriparatide is a drug that is better known thanks to observational studies. It was approved for … Address correspondence to Dr. Díez-Pérez; E-mail: ADiez{at}parcdesalutmar.cat ER -